{
  "ticker": "LRMR",
  "company_name": "Larimar Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04255680",
      "title": "A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Friedreich Ataxia",
      "start_date": "2020-01-14",
      "completion_date": "2020-06-30",
      "enrollment": 0,
      "sponsor": "Larimar Therapeutics, Inc."
    },
    {
      "nct_id": "NCT04519567",
      "title": "Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Friedreich Ataxia",
      "start_date": "2020-07-31",
      "completion_date": "2021-03-16",
      "enrollment": 0,
      "sponsor": "Larimar Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05028764",
      "title": "Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Friedreich Ataxia, Healthy Volunteers",
      "start_date": "2021-08-04",
      "completion_date": "2022-02-04",
      "enrollment": 0,
      "sponsor": "Larimar Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05579691",
      "title": "A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Friedreich Ataxia",
      "start_date": "2022-09-21",
      "completion_date": "2023-12-04",
      "enrollment": 0,
      "sponsor": "Larimar Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06681766",
      "title": "A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Friedreich Ataxia",
      "start_date": "2024-12-06",
      "completion_date": "2025-04-28",
      "enrollment": 0,
      "sponsor": "Larimar Therapeutics, Inc."
    },
    {
      "nct_id": "NCT04176991",
      "title": "Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Friedreich Ataxia",
      "start_date": "2019-12-11",
      "completion_date": "2020-10-31",
      "enrollment": 0,
      "sponsor": "Larimar Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06447025",
      "title": "An Open Label Extension Study of CTI-1601 in Subjects With Friedreich's Ataxia",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "PHASE2",
      "condition": "Friedreich Ataxia",
      "start_date": "2024-01-25",
      "completion_date": "2027-01",
      "enrollment": 0,
      "sponsor": "Larimar Therapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 7,
    "by_phase": {
      "": 2,
      "PHASE1": 3,
      "PHASE2": 2
    },
    "by_status": {
      "COMPLETED": 5,
      "TERMINATED": 1,
      "ENROLLING_BY_INVITATION": 1
    },
    "active_trials": 1,
    "completed_trials": 5,
    "conditions": [
      "Friedreich Ataxia",
      "Friedreich Ataxia, Healthy Volunteers"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:19:45.165026",
    "search_query": "Larimar Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Larimar+Therapeutics,+Inc."
  }
}